We’re pleased to share that Variational AI will be participating in the CCG North American UGM & Conference 2026, taking place June 23–26, 2026 in Montreal, Canada.
The CCG UGM & Conference is a four-day event focused on computational chemistry, drug design, and discovery across small molecules, peptides, and biologics, combining hands-on workshops with scientific presentations, posters, and networking.
Featured scientific presentation (Thursday, June 25 | 13:30–14:00)
Alex Perryman (Principal Scientist, Variational AI) will present:
“Adventures in Drug Discovery and How MOE Helped Advance it in Multiple Projects”
Talk overview
Published work from the Repare Therapeutics team will be presented, highlighting structure-based drug design (SBDD) approaches in MOE that helped advance multiple oncology programs into clinical trials. This includes the discovery of selective inhibitors of PkMYT1 (leading to RP-6306 / Lunresertib) and PLK4 (RP-1664), as well as work on Pol-theta (polymerase and ATPase domains), including the ATPase inhibitor RP-2119 and clinical candidate RP-3467.
An update will also be shared from the Variational AI collaboration with the Agora Open Science Trust and Enamine on PRMT6, a target for Spinal Bulbar Muscular Atrophy (SBMA). Generative AI outputs from Enki were docked against a novel PRMT6 allosteric site and analyzed with MOE, leading to a new hit with a novel scaffold in under three months.
Meet the team
If you’ll be attending and would like to connect during the conference, reach out to bd@variational.ai to schedule time.